GlassScriptPhysician profile
Haley Moore Haught
NPI 1114280633
$5,448.59
in general payments reported to CMS, 2019-2025
32 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $995 · 2022: $821 · 2023: $1,076 · 2024: $1,319 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,633.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $638.22 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $503.64 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $498.46 | 2022-2025 | |
| Novo Nordisk INC | $436.28 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $430.00 | 2021-2025 | |
| Lilly USA, LLC | $388.51 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $340.05 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $256.89 | 2021-2025 | |
| Eisai INC. | $243.92 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $231.52 | 2021-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.08 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $190.40 | 2023-2025 | Rexulti |
| Alkermes, INC. | $189.40 | 2024-2025 | Vivitrol |
| Astellas Pharma US INC | $115.32 | 2021-2025 | Veozah, Myrbetriq |
| Phathom Pharmaceuticals, INC. | $102.76 | 2023-2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $102.06 | 2021-2025 | |
| Exact Sciences Corporation | $89.98 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $86.08 | 2021-2022 | |
| Lundbeck LLC | $79.52 | 2023-2025 | Rexulti |
| Esperion Therapeutics, INC. | $69.42 | 2021-2025 | Nexletol |
| Abbott Laboratories | $43.01 | 2021-2022 | |
| Ardelyx, INC. | $33.63 | 2025 | Ibsrela |
| Biogen, INC. | $28.24 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $23.48 | 2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $22.71 | 2021 | |
| Sumitomo Pharma America, INC. | $16.94 | 2025 | Gemtesa |
| Organon LLC | $16.68 | 2021 | |
| Indivior INC. | $16.67 | 2022 | |
| Smith+Nephew, INC. | $16.11 | 2023 | Regranex, Collagenase Santyl |
| Teva Pharmaceuticals USA, INC. | $14.81 | 2025 | Austedo Xr |
| Sanofi Pasteur INC. | $13.55 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Haught listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.